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DNA vaccines have the capacity to induce strong Th1-biased immune responses that are of major importance to providing
protection against intracellular pathogens. In the present study we have focused on the role played by type I IFN in immune
responses induced after DNA vaccination. Mice lacking the IFNAR1 chain of the type I IFN receptor (IFNAR K/O mice) were
immunized with a plasmid encoding glycoprotein C of pseudorabies virus (PRV-gC). After DNA vaccination, wild-type (WT)
mice showed features characteristic of Th1 immune responses, such as high IgG2a:IgG1 anti-PRV Ab ratio and antigen-
specific IFN-g production by spleen cells. In contrast, IFNAR K/O mice showed a significantly lower IgG2a:IgG1 Ab ratio and
IFN-g production. In addition, the percentage of CD81 and B lymph-node cells expressing CD69 after PRV-gC DNA
vaccination was lower in IFNAR K/O than in WT mice. These results support a major role played by type I IFN in shaping Th1
immune responses after DNA vaccination. Codelivery of plasmids encoding IL-12 and IL-18 along with the plasmid encoding
PRV-gC restored Th1 responses in IFNAR K/O mice. © 2001 Academic Press
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iINTRODUCTION
Direct injection of plasmid DNA encoding protective
antigens has been shown to induce both humoral and
cellular immune responses as well as protection against
infection, emphasizing the interest of this novel approach
to vaccination (for reviews see Gurunathan et al., 2000;
Babiuk et al., 1999; Tighe et al., 1998). One important
dvantage of DNA vaccines is their ability to allow anti-
en presentation by both MHC class I and II molecules
Whitton et al., 1999). Since successful induction of im-
une responses generally requires the presence of ad-
uvants, another advantage of DNA vaccines is that they
ontain specific nucleotide sequences that act as adju-
ants. It is indeed well established that bacterial DNA
nd synthetic oligonucleotides containing unmethylated
pG motifs cause strong activation of B cells, T cells, NK
ells, macrophages, and dendritic cells (Krieg et al.,
995; Sun et al., 1998; Asakura et al., 2000; Hartman et al.,
999; Jakob et al., 1998, Sparwasser et al., 1998).
Th1 specific effector functions were shown to be im-
ortant for protective immune responses against intra-
ellular pathogens, including viruses (Ramshaw et al.,
997). Therefore understanding the mechanisms in-
olved in Th1 polarization of the immune response after
NA vaccination is an important issue for development
f antiviral vaccines. The potent immunostimulatory ac-
ivity of bacterial DNA controlled by unmethylated CpG
1 a
e
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197inucleotide motifs may have important implications for
riming and maintenance of Th1-type immune re-
ponses (Chu et al., 1997). These unmethylated CpG
equences augment the expression of costimulatory
olecules on antigen-presenting cells (APC) and trigger
hem to synthesize cytokines such as IL-12, IL-18, and
ype I IFN (Sato et al., 1996; Roman et al., 1997; Jakob et
l., 1999). The ability of APC to present antigens to Th
ells is therefore enhanced and the cytokines they re-
ease can contribute to bias Th differentiation toward
h1. The major role played by IL-12 and IL-18 in the
haping of Th1 responses is well established (Okamura
t al., 1998). Type I IFN plays a major role in T- and B-cell
ctivation triggered by unmethylated CpG motifs (Sun et
l., 1998). However the way type I IFN acts on lympho-
ytes is still unclear (Sun and Sprent, 2000). In addition,
he possible adjuvant role of type I IFN on antigen-
pecific immune responses to DNA vaccination has not
een investigated.
To evaluate in vivo the effects of type I IFN on antiviral
mmune responses induced by DNA vaccination, we took
dvantage of mice deficient in a functional type I IFN
eceptor (IFNAR1) as an animal model (Muller et al.,
994). The viral model we used is pseudorabies virus
PRV), a member of the alphaherpesvirus subfamily, re-
ponsible for economically important diseases in do-
estic animals (Mettenleiter, 1996). Among several viral
nvelope antigens, glycoprotein C (gC) was shown to be
mportant in the initiation of the immune response and to
ct as a major target for cytotoxic T-lymphocytes (Zuck-
rmann et al., 1990).
0042-6822/01 $35.00
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198 TUDOR ET AL.In the present study, several criteria of the immune
response induced by a plasmid coding for PRV-gC were
evaluated in type I IFN receptor knockout mice. The
parameters tested included the specific isotype antibody
response (IgG1 vs IgG2a) and IFN-g synthesis after in
itro antigen-specific restimulation as markers of Th1
esponses (Mosmann and Coffman, 1989). To investigate
he activation of T and B cells following DNA vaccination,
he expression of CD69 (an early activation marker) was
onitored by flow cytometry analysis. Our results show
hat type I IFN was involved in the shaping of a Th1-type
mmune response to DNA vaccine encoding the PRV-gC.
RESULTS
RV-gC DNA vaccination triggers antigen-specific
ntibody production in IFNAR K/O and wild-type
WT) mice
Mice received 100 mg of DNA encoding PRV-gC
(VR1055-gC) administered id in both ears on days 0 and
14. The IgG antibody response was monitored by PRV-
specific ELISA in serum samples from IFNAR K/O and
WT mice. In both mouse strains anti-PRV-IgG production
increased after day 7 and reached its maximum 1–2
weeks after booster injection (Fig. 1). The amounts of
anti-PRV-IgG were similar at all time points in IFNAR K/O
and WT mice (P . 0.05) (Fig. 1). This implies that both
FIG. 1. Anti-PRV IgG Ab production in IFNAR K/O mice compared with
WT after PRV-gC DNA vaccination. PRV-specific IgG levels were mea-
sured by ELISA. Each group of mice (n 5 5) was immunized id with 100
mg of VR1055-gC at day 0 and 14. Mice were bled each week and the
sera were diluted 1:30 for ELISA. Data represent Ab levels (OD at 450
nm) WT mice (l—l); IFNAR KO mice (l---l). Values and bars
represent mean and SEM for five mice. Results from one representative
experiment of a group of 2 are shown.ouse strains exhibited the ability to respond to DNA-
ncoded PRV-gC.educed IgG2a:IgG1 anti-PRV antibody ratio in IFNAR
/O mice
The amount of IgG2a and IgG1 Ab produced upon
accination with VR1055-gC was assayed by PRV-spe-
ific ELISA in serum samples. WT mice exhibited signif-
cantly higher levels of anti-PRV-IgG2a than of anti-PRV-
gG1 Ab after the first plasmid injection (P , 0.01 at day
4) and after the booster injection (P , 0.001 at days 23
nd 27) (Fig. 2A). By contrast, IFNAR K/O mice raised
imilar levels of anti-PRV-IgG2a and anti-PRV-IgG1 Ab
fter the first and second plasmid injection (Fig. 2B).
ccordingly, IgG2a:IgG1 ratios were significantly lower in
FNAR K/O than in WT mice (1.92 vs 6.71 at day 23, P ,
.01) (Fig. 2). These data were obtained with OD mea-
ured in 1:30 diluted sera. Similar differences were also
bserved with OD measured in 1:15 or 1:45 diluted sera,
FIG. 2. Reduced IgG2a Ab level and IgG2a:IgG1 Ab ratio in IFNAR
K/O mice compared to WT mice after PRV-gC DNA vaccination. PRV-
specific IgG1 ( ) and IgG2a (M) levels were measured by ELISA. Each
group of mice (n 5 5) was immunized id with 100 mg of VR1055-gC at
day 0 and 14. Mice were bled each week and the sera were diluted 1:30
for ELISA. Data represent Ab levels (OD at 450 nm) and IgG2a:IgG1
ratio (l—l). (A) WT mice. (B) IFNAR K/O mice. Values and bars
represent mean and SEM for five mice. Results from one representative
experiment of a group of 5 are shown.
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199TYPE I IFN MODULATION RESPONSES TO DNA VACCINATIONor with Ab titers calculated by limiting dilutions (not
shown). The high ratio of IgG2a to IgG1 Ab seen in WT
mice indicates that PRV-gC DNA vaccination elicited a
bias toward Th1 immune responses. The reduced IgG2a:
IgG1 Ab ratio observed in K/O mice suggests that type I
IFN contributed to the shaping of Th1 responses.
PRV-restimulated splenocytes of vaccinated IFNAR
K/O mice synthesized less IFN-g
To test the hypothesis of a role for type I IFN in
shaping Th1 responses, we have compared IFN-g
production by splenocytes of IFNAR K/O and WT mice
inoculated twice with VR1055-gC. IFN-g production
as quantified by ELISA in the supernatant of spleno-
ytes cultured 48 h with PRV antigen. The amount of
FN-g secreted by splenocytes of both mouse strains
was significantly increased (P , 0.0001 in WT and P ,
0.05 in IFNAR K/O mice) after VR1055-gC vaccination
as compared to nonvaccinated mice (Figs. 3A and 3B).
However following VR1055-gC inoculation, WT spleno-
cytes produced 3.6 times more IFN-g after in vitro
estimulation with PRV antigens than IFNAR K/O
plenocytes (P , 0.0001) (Figs. 3A and 3B). Thus, in
he absence of a functional type I IFN receptor, spleno-
ytes of VR1055-gC vaccinated mice have a reduced
bility to secrete IFN-g.
he percentage of CD81 and B lymph-node cells
expressing CD69 following VR1055-gC vaccination
is reduced in IFNAR K/O mice
As type I IFN are known to affect the expression of
activation markers on T and B cells (Sun and Sprent,
2000; Sun et al., 1998), we have assessed the level of
CD69 (early activation antigen) expression by T and B
lymph-node cells. Draining lymph-node cells of both
mouse strains were stained with anti-CD69 mAb in com-
bination with anti-CD8, anti-CD4, or anti-sIg mAbs at 18
and 48 h after VR1055-gC injection and analyzed by flow
cytometry.
VR1055-gC injection significantly increased the per-
centage of CD81 and B cells expressing CD69 at 18 h
(P , 0.02 and P , 0.0002, respectively) in draining
lymph nodes of WT mice but not of IFNAR K/O mice
(Figs. 4A and 4B). By contrast the percentage of CD41
cells expressing CD69 in both mouse strains did not
significantly increase upon VR1055-gC injection (Figs.
4A and 4B). The differential pattern of CD69 ex-
pression by T and B cells is shown for one individual
(Fig. 5).
Thus, our results show that early activation of CD81 T
and B cells (shown by CD69 expression) in response to
DNA-encoded PRV-gC required a functional type I IFN
signaling pathway. FCodelivery of IL-12 and IL-18 encoding plasmids
restored Th1 responses but not CD69 expression
in VR1055-gC-vaccinated IFNAR K/O mice
Plasmids encoding IL-12 and IL-18 (pWRG3169-mIL-12
and pCR3.1<mIL-18) were coinjected with VR1055-gC to
IFNAR K/O mice to test whether Th1 responses (IgG2a:
IgG1 ratio and IFN-g production) could be restored by
FN-g-promoting cytokines.
IL-12/IL-18 DNA coinjection significantly enhanced IFN-g
production by in vitro PRV-restimulated splenocytes from both
IFNAR K/O and WT mice as compared to mice injected with
FIG. 3. Reduced IFN-g production by PRV-restimulated IFNAR K/O
splenocytes. Mice were immunized id with 100 mg of VR1055-gC at day
and 14. Some mice were coinjected with IL-12 and IL-18 plasmids
gC/IL-12/IL-18) or with empty plasmid (gC/pcDNA3) as a negative
ontrol for IL-12/IL-18. Control mice were not injected. Spleens were
ollected 2 weeks after booster injection and cell cultures were stim-
lated with either PRV antigen or culture medium as negative control,
r PMA and ionomycin as a positive control. The level of IFN-g was
measured 48 h later by ELISA. IFN-g levels were ,0.2 ng/ml in negative
controls and .20 ng/ml in positive controls. One of three representa-
tive experiments is shown. (A) WT mice; (B) IFNAR KO mice.VR1055-gC only (Fig. 3A, P , 0.001, and Fig. 3B, P , 0.02).
urthermore after IL-12 and IL-18 DNA coinjection, spleno-
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200 TUDOR ET AL.cytes of IFNAR K/O and WT mice displayed equivalent
ability to produce IFN-g (Fig. 3B compared to Fig. 3A).
Coinjection of the plasmids coding for IL-12/IL-18 to
VR1055-gC-vaccinated IFNAR K/O mice increased IgG2a
and decreased IgG1 Ab levels (Fig. 6A compared to Fig.
2B). Thus, whereas IgG2a:IgG1 Ab ratios were always ,
2 in VR1055-gC-vaccinated IFNAR K/O mice (Fig. 2B),
they increased up to 8 in IL-12/IL-18 injected mice (Fig.
6A). Codelivery of IL-12/IL-18 DNA to WT mice also re-
FIG. 4. The percentage of CD81 and B lymph-node cells expressin
ven after codelivery of IL-12/IL-18 plasmids. Each group of mice (n
), which were injected with PBS. One group of mice was coinjected
ith empty plasmid (gC/pcDNA3) as a negative control for IL-12/IL-
ymph-node cells were double-stained for CD4, CD8, sIg, and CD69
FNAR K/O mice.sulted in an increase of IgG2a Ab and the IgG2a:IgG1 Ab
ratio (Fig. 6B compared to Fig. 2A).The percentage of CD81 and B cells expressing
CD69 in the draining lymph node of IFNAR K/O mice
was not increased upon coinjection of IL-12/IL-18 DNA
with VR1055-gC at 18 and 48 h (Figs. 4A and 4C).
However when administered to WT mice, IL-12/IL-18
DNA significantly increased the percentage of CD81
and B cells expressing CD69 at 48 h (Fig. 4D, P , 0.05
nd P , 0.01, respectively) but not at 18 h (Fig. 4B). At
oth time points the percentage of CD691 CD41 was
is lower in PRV-gC-vaccinated IFNAR K/O as compared to WT mice
as injected id with 100 mg of VR1055-gC, except control mice (n 5
-12 and IL-18 plasmids (gC/IL-12/IL-18); another group was injected
h later (Figs. 4A and 4B) and 48 h later (Figs. 4C and 4D) draining
s and bars represent mean and SEM for six mice. (B, D) WT; (A, C)g CD69
5 6) w
with IL
18. 18not significantly altered by IL-12/IL-18 DNA codelivery
(Figs. 4B and 4D).
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201TYPE I IFN MODULATION RESPONSES TO DNA VACCINATIONAn empty plasmid (pcDNA3) was coinjected with
VR1055-gC instead of the IL-12 and IL-18 coding plas-
mids to control the specificity of their effect. The empty
plasmid codelivered with VR1055-gC had no effect on
IFN-g production (Fig. 3) but did increase the level of
gG1 and IgG2a Ab in both mouse strains (Figs. 6C and
D vs Fig. 2) without affecting the IgG2a:IgG1 ratio.
herefore the adjuvant effect of the control plasmid on
otal Ab production (presumably due to CpG motifs) (Chu
t al., 1997) was significantly different from that exerted
y IL-12/IL-18 coding plasmids. The empty plasmid code-
ivered with VR1055-gC instead of IL-12/IL18 DNA had no
ffect on the percentage of WT lymph-node cells ex-
FIG. 5. Differential pattern of expression of CD69 by T and B cells betw
K/O) was injected id with 100 mg of VR1055-gC; 18 h later, draining l
taining for CD69 (FL2) and CD4 (FL1) or CD8 (FL3) or B cells (FL1) is s
pper windows contain the CD69-positive cells. The percentage of sing
epresentative individual are shown.ressing CD69 (Figs. 4B and 4D).
T
iDISCUSSION
To gain insight into the role played by type I IFN in
NA vaccination to viral antigens, we examined antigen-
pecific immune responses triggered by DNA encoding
RV-gC in WT and IFNAR K/O mice. PRV-gC DNA vacci-
ation of WT mice induced antigen-specific IFN-g pro-
uction by splenocytes and a high ratio of IgG2a:IgG1
nti-PRV Ab in serum. These features indicated a bias
oward Th1 immune responses. In the absence of a
unctional type I IFN signaling pathway, PRV-gC DNA
mmunization resulted in a much lower IgG2a:IgG1 Ab
atio and decreased IFN-g production by splenocytes.
NAR K/O and WT mice. Each group of mice (seven WT and eight IFNAR
ode cells were double-stained for CD4, CD8, sIg, and CD69. Double
Quadrant limits were set according to matching isotype dot plots. The
double-positive cells are shown for each dot plot. Dot plots from oneeen IF
ymph-n
hown.hese differences between IFNAR K/O and WT mice
mmune responses could reflect a different availability of
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202 TUDOR ET AL.PRV-gC antigen. However the observation that the total
IgG Ab response did not differ between the two strains of
mice suggested that IFNAR K/O and WT mice have
similar ability to take up the DNA-encoded viral antigen
and then transcribe/translate it. Therefore the reduced
ability of IFNAR K/O mice to generate Th1 responses to
PRV-gC DNA points to a regulatory role for type I IFN in
the process leading to Th1-biased immune responses.
To understand the pathways by which type I IFN favors
a bias toward Th1 immune responses, we investigated
early T- and B-cell activation in the lymph node draining
the site of PRV-gC DNA injection. Indeed, DNA or CpG
motifs are known to induce up-regulation of cell adhe-
sion/activation molecules including CD69 and B7–2 in a
process requiring type I IFN (Kranzer et al., 2000; Sun et
l., 1998). CD69 is an activation marker expressed shortly
fter lymphocyte activation and acts as a costimulatory
FIG. 6. Codelivery of IL-12/IL-18 plasmids enhanced the IgG2a Ab
level and IgG2a:IgG1 Ab ratio in IFNAR K/O mice immunized with
PRV-gC DNA. PRV-specific IgG1 ( ) and IgG2a (M) levels were mea-
sured by ELISA. Each group of mice (n 5 5) (B, D: WT; A, C: IFNAR K/O
mice) was immunized id with 100 mg of VR1055-gC and coinjected with
IL-12 and IL-18 plasmids (A and B) or with empty plasmid (C and D) at
day 0 and 14. Mice were bled each week and the sera were diluted 1:30
for ELISA. Data represent Ab levels (OD at 450 nm) and IgG2a:IgG1
ratio (l—l). Values and bars represent mean and SEM for five mice.
Results from one representative experiment out of five is shown.olecule (Borrego et al., 1999). DNA vaccination of WT
ice resulted in a rapid increase in the percentages ofD81 and B lymphocytes expressing CD69. By contrast,
the percentage of CD81 and B lymph-node cells express-
ing CD69 in IFNAR K/O mice remained at basal levels.
The percentage of CD41 cells expressing CD69 was only
oderately increased and there was no significant dif-
erence between WT and IFNAR K/O mice. Therefore
D81 and B cells were the first subsets of lymphocytes
displaying an activated phenotype in regional lymphoid
tissues and type I IFN played a critical role in this early
process. The consequences of rapid activation of CD81
and B cells for shaping Th1 responses may be of two
sorts.
First, activated CD81 T cells could be a major early
ource of IFN-g that will subsequently contribute to the
ifferentiation of Th0 into Th1 cells. In fact in mice, in
ontrast to humans, the type I IFN signaling pathway
STAT4) leading Th cells to produce IFN-g is not func-
ional. In contrast, murine CD81 T cells were found to
produce IFN-g in the absence of STAT4 activation (Farrar
nd Murphy, 2000). Therefore, a STAT4-independent
athway involving CD81 T-cell activation by type I IFN
could provide the cytokine microenvironment allowing Th
cells differentiation into Th1 cells.
Second, type I IFN may act directly on B cells. Previous
work using anti-IgD immunization in mice has shown
that type I IFN regulates Ig-isotype selection through a
direct effect on B cells (Finkelman et al., 1991). Moreover
CpG DNA in vivo was shown to induce B cells to prolif-
rate and secrete Ig (Krieg et al., 1995). We propose
herefore that type I IFN supported a predominant IgG2a
b response after PRV-gC DNA vaccination by directly
ctivating B cells (proliferation and isotype selection).
Since IL-12 and IL-18 are known to favor Th1 orienta-
ion of immune responses (Okamura et al., 1998), we
nvestigated in our experimental conditions whether the
dministration of plasmids encoding IL-12 and IL-18
ould restore Th1 responses. IL-12/IL-18 DNA delivery
ogether with PRV-gC DNA strongly increased the IgG2a:
gG1 Ab ratio and PRV-specific IFN-g production by
plenocytes in IFNAR K/O mice and to a lesser extent in
T mice. Thus IL-12/IL-18 DNA codelivery has restored
he antigen-specific-Th1 responses in IFNAR K/O mice.
hese results are in accordance with other studies
howing an enhancement of IFN-g secretion after injec-
tion of plasmids encoding IL-12 (Sin et al., 1999) or IL-18
Kremer et al., 1999). In addition, in some models IL-12
odelivery increased the IgG2a:IgG1 ratio (Chow et al.,
998), while in other models IL-12 or IL-18 induced an
verall decrease of Ab production (Kim et al., 1997).
A first explanation for the effect of IL-12 and IL-18
bserved in our experimental model is their ability to
irectly trigger Th0 cell differentiation into Th1. IL-12/
L-18 DNA codelivery did not increase the percentage of
D81 and B cells expressing CD69 in IFNAR K/O mice,although the percentage increased in WT mice at 48 h.
This suggested that in our experimental model IL-12 and
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203TYPE I IFN MODULATION RESPONSES TO DNA VACCINATIONIL-18 could restore Th1 responses without restoring the
pathway leading to early CD81 and B cell activation.
Therefore we propose that type I IFN sustains Th1 re-
sponses through its action on CD81 and B cells,
hereas IL-12 and IL-18 can act directly on CD41 cells.
owever we did not observe any increase in the per-
entage of CD41 cells expressing CD69 after IL-12/IL-18
NA codelivery in both WT and IFNAR K/O mice.
The codelivery of IL-12 and IL-18 DNA in vivo may have
ompensated for deficient synthesis of these cytokines
n IFNAR K/O mice, although we have not formally proven
he latter. However this hypothesis is not sustained by
ther in vivo studies based on inoculation of live virus
LCMV) or inactivated virus particles (HSV1), showing
hat type I IFN inhibits or does not modify IL-12 produc-
ion, respectively (Cousens et al., 1997; Riffault et al.,
000).
The IFNAR1 chain of the type I IFN receptor was
hown to facilitate the recruitment of IFN-g-activated
transcription factors (Takaoka et al., 2000). Therefore in
he absence of the IFNAR1 chain in IFNAR K/O mice,
igher concentrations of IFN-g may be required to effi-
ciently trigger the IFN-g receptor-signaling pathway.
L-12 and IL-18 DNA codelivery with PRV-gC DNA could
ufficiently increase the amount of IFN-g locally available
in IFNAR K/O mice to restore IFN-g-mediated responses.
In conclusion our experiments show that type I IFN
plays an important role in Th1 polarization of the immune
response induced by DNA vaccination to a viral protein.
Our results imply therefore that tailoring of DNA se-
quences involved in type I IFN induction will constitute a
key parameter for the improvement of DNA vaccines by
enhancing Th1 responses. This is of major importance
for protection against intracellular pathogens, especially
viruses.
MATERIALS AND METHODS
Mice
Eight- to ten-week-old female pathogen-free mice, ei-
ther deficient in type I IFN receptor function as a result of
inactivation of the IFNAR 1 gene (IFNAR K/O, or A129) or
wild-type 129SvEv control mice (WT, or 129), were both
originally purchased from B&K Universal Limited (North
Humberside, U.K.). Mice were bred within the INRA an-
imal care facilities (Jouy-en-Josas, France) and handled
in accordance with institutional guidelines for animal
care and use.
Plasmids
A plasmid (VR1055-gC) driving the expression of
PRV-gC protein under the control of the HCMV promoter
was used in this study. A plasmid construct (kindly pro-
vided by Dr. Andre´ Jestin, AFSSA, Ploufragan, France)
containing a 4.1-kb PstI fragment of PRV (NIA3 strain)genomic DNA was used as source of gC coding se-
quence (GenBank Accession No. D49437). The 1511-bp
DraI–HinfI fragment bearing the complete gC reading
frame was purified and inserted in the proper orientation
at the EcoRV site of the VR1055 expression vector (kindly
provided by Dr. Robert Zaugg, Vical, San Diego, CA).
Expression of gC was verified by flow cytometry analysis
on transfected mouse fibroblast cells.
Plasmids pWRG3169-mIL-12 (obtained from Dr. A. L.
Rakhmilevich, University of Wisconsin, Madison, WI) and
pCR3.1::IL-18 (provided by Dr. C. Locht, Pasteur Institute,
Lille, France) allowed HCMV promoter-controlled ex-
pression of murine IL-12 (p35 and p40 subunits) and
IL-18, respectively (Rakhmilevich et al., 1996; Kremer et
l., 1999). All plasmids were amplified in Escherichia coli
H5a and purified by standard cleared lysate method,
phenol chloroform extraction, and two rounds of banding
by centrifugation on cesium chloride–ethidium bromide
gradient (Sambrook et al., 1989).
DNA vaccination protocol
Mice were inoculated id on day 0 and 14 in the dorsal
side of each ear with 50 mg VR1055-gC in a volume of 25
ml using a 22-G needle (100 mg VR1055-gC delivered in
total) as described (Casares et al., 1997; Riffault et al.,
2000). In the experiments where mice were coinjected
with several plasmids, 50 mg of each plasmid, coding for
IL-12 and IL-18, were mixed prior to injection with 100 mg
f VR1055-gC. In these experiments control mice were
noculated with 100 mg of the empty vector pcDNA3
(Invitrogen Groningen, The Netherlands) mixed prior to
injection with 100 mg of VR1055-gC.
Antigen-specific in vitro-restimulation of splenocytes
Injected mice were anesthetized with methoxyflurane
and after sacrifice by cervical dislocation their spleens
were harvested. Spleen cells, after RBC lysis, were cul-
tured at 2 3 106 cells/ml in 96-well flat-bottomed micro-
titer plates (Falcon 3072) and stimulated with an m.o.i. of
10 TCID50 of the vaccine PRV strain Bartha, kindly pro-
vided by Dr. A. Jestin (AFSSA, Ploufragan, France). For
positive controls, spleen cells were treated with PMA (10
ng/ml, Sigma) and ionomycin (1 mg/ml, Calbiochem).
upernatants were harvested from cultures after incuba-
ion at 37°C in 5% CO2 for 48 h and frozen at2 20°C until
titration.
IFN-g ELISA
Culture supernatants were tested in duplicate for
FN-g using specific ELISA. Microtiter plates (Immulon,
HB) were coated with 100 ml anti-IFN-g capture Ab
(R4–6A2, PharMingen) at a concentration of 4 mg/ml
overnight at 4°C. The plates were washed five times with
PBS/Tween and blocked with 100 ml per well of 2%
bovine serum albumin in PBS for 2 h at 37°C. Then the
z
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204 TUDOR ET AL.plates were washed five times and incubated with sam-
ples and standard (recombinant murine IFN-g, from Gen-
yme) overnight at 4°C. One hundred microliters of bio-
inylated anti-IFN-g (XMG1.2, PharMingen) at a concen-
tration of 1 mg/ml was added to each well and incubated
t 4°C for 3 h. The plates were then washed five times,
00 ml of streptavidine-horseradish peroxidase (Immuno-
ure Pierce, 1 mg/ml) was added, and the mixture was
incubated at 4°C for 1 h. Following washing, the sub-
strate was added and absorbance was measured using
an ELISA plate reader. The concentration of IFN-g in the
samples was determined by comparison with recombi-
nant murine IFN-g.
Flow cytometry analysis of CD69 expression by CD4,
CD8, and B cells
After injection of the plasmids id, mouse auricular
lymph nodes were harvested and cells were prepared by
lymph-node disruption; 1 3 106 cells were distributed in
96-well flat-bottomed microtiter plates (Falcon 3072).
Cells were double stained for 30 min on ice with PE-
conjugated anti-CD69 (clone H1.2F3) (PharMingen) in
combination with FITC-conjugated anti CD4 (clone CT-
CD4), TC-conjugated anti CD8 (clone CT-CD8a) (Caltag),
or biotin-conjugated goat anti-mouse IgG (Sigma) fol-
lowed by FITC-conjugated streptavidin (PharMingen).
Matching isotype controls were used in each case. Data
were collected on 30,000 cells using a FACScan (Bec-
ton–Dickinson) flow cytometer and analysis was per-
formed on CellQuest software (Becton–Dickinson). Cells
were electronically gated according to light scatter prop-
erties to exclude cell debris.
Isotype-specific antibody assay
Serum samples were collected by retro-orbital bleed-
ing at different time points and analyzed for the presence
of PRV-specific Abs by ELISA. Briefly, microtiter plates
(Falcon 3915, Becton–Dickinson) were coated with PRV
antigen (Kaplan strain: concentrated and inactivated an-
tigen preparation, kindly provided by Dr. J.-C. Audonnet,
Merial, Lyon, France) at 0.08 mg/ml in carbonate–bicar-
bonate buffer (0.1 M, pH 9.5) overnight at 4°C. After
incubation with 150 ml of 0.5% bovine serum albumin in
BS/Tween for 1 h at 37°C, 100 ml of prediluted test sera
(1:30) was added in duplicate and incubated for 2 h at
37°C. After washing, Abs were detected with horserad-
ish peroxidase-conjugated rat anti-mouse IgG (1:4000,
Biosys), IgG1, or IgG2a (1:2000, PharMingen). Enzymatic
reaction was developed by adding 3,39,5,59-tetramethyl-
benzidine (TMB) (Kirkegaard & Perry Laboratories Inc.)
as a substrate. The absorbance was measured at 450
nm after addition of 1 M phosphoric acid.Data analysis
All values were expressed as mean and standard error
of the mean (SEM). Statistical analysis of the experimen-
tal data and controls was conducted by Student’s t test.
Significance was defined at P , 0.05 in statistical anal-
ysis.
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